May 14, 2021 10:34am
A scorecard of earnings releases of 35 covered companies
The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status"
28 to date
|
COMPANY |
SYMBOL | NET INCOME | Q1/21 LOSS | Q1/21 LPS | Q1/21 CASH | RUNWAY |
|---|---|---|---|---|---|---|
|
Chinook Therapeutics formerly, Aduro Biotech (ADRO) |
KDNY | -$37.2 m | -$0.08 | $222.6 m | 2023 | |
|
Alnylam Pharmaceuticals |
ALNY | -$200 M | -$1.71 |
$1.71 B |
2024 | |
| Applied Genetic Technologies | AGTC | Monday, 5/17 |
|
|||
|
Athersys
|
ATHX | -$26.5 m | -$0.13 | $64.2 m | 2022 | |
|
Adverum Biotechnologies |
ADVM | -$28.4 m | -$0.29 | $404 m | Q1/23 | |
|
AxoGen
|
AXGN | -$6.7 m | -$0.16 | $97.2 m | Q1/23 | |
|
Bellicum Pharmaceuticals |
BLCM |
|
||||
|
BioLife Solutions |
BLFS |
|
-$1.1 m | -$0.03 |
$89.1 m |
2023 |
| Biostage | BSTG | Q1/21 | ||||
|
bluebird bio
|
BLUE | -$205.8 m | -$3.07 | $1.09 B | 2023 | |
|
Brainstorm Cell Therapeutics
|
BCLI | -$6.6 m | -$0.19 | $40 M | 2022 | |
|
Caladrius Biosciences. |
CLBS | -$8.1 m | -$0.19 | $111.5 m |
2023 |
|
| Cellectis SA | CLLS |
|
-$12 m | -$0.28 | $231 m | 2023 |
|
CRISPR Therapeutics |
CRSP | -$113.2 M | -$1.51 | $1,806 m | 2023 | |
|
Editas Medicine |
EDIT |
|
-$56.7 m | -$0.86 | $732.2 m | 2023 |
|
Fate Therapeutics |
FATE | -$45 m | -$0.48 | $888.4 m | 2023 | |
|
Global Blood Therapeutics |
GBT | -$74.9 m | -$1.21 | $482 m | 1H/2023 | |
|
Homology Medicine |
FIXX | -$1.1 m | -$0.02 |
$188.6 m $49.4 m raised in April |
Q1/23 | |
|
Intellia Therapeutics |
NTLA | -$46.2 m | -$0.69 | $600.8 m | 2023 | |
|
Precigen formerly Intrexon |
PGEN | -$17.3 m | -$0.11 | $209.3 m | 2022 | |
|
Ionis Pharmaceuticals |
IONS |
|
-$90 m | -$0.64 | $1.8 B | N/A |
| Mesoblast | MESO |
|
|
|||
| MiMedx Group |
MDXG |
|
-$8.41 m |
-$0,09 | $84.7 m | 2023 |
|
Pluristem Therapeutics |
PSTI | 2022 | ||||
|
ReNeuron Group |
RENE.L | |||||
|
Regenxbio
|
RGNX | -$50.1 m | -$1.20 | $656.5 m | 2H/23 | |
|
Sage Therapeutics |
SAGE | -$95.8 m | -$1.64 | $2 B | N/A | |
|
Sangamo Biosciences |
SGMO | -$45.9 m | -$0.32 | $629.5 m | 2024 | |
|
Solid Biosciences |
SLDB |
-$16.9 m |
-$0.19 | $268.5 m | Q4/22 | |
|
Ultragenyx Pharmaceuticals |
RARE | -$136.1 m | -$2.03 | $1 B | N/A | |
|
uniQure N.V.
|
QURE | -$41.6 m | -$0.91 |
$260.8 m $450 from CSL Behring used $35 of $135 from Hercules -debt vehicle $200 m fro SVBLeerink |
2H/24 | |
|
Verastem Oncology |
VSTM | -$15 m | -$0.09 | $127.1 m | Q1/24 | |
|
Vericel
|
VCEL | -$3.3 m | -$0.07 | $110 m | 2023 | |
|
Voyager Therapeutics |
VYGR |
|
-$21.6 m | -$0.58 | $153.1 m | Q1/23 |
